MERS-CoV Spike Glycoprotein RBD (Strain EMC/2012) (recombinant)

Middle East respiratory syndrome coronavirus (MERS-CoV) spike glycoprotein is a viral structural protein that contains the receptor-binding domain (RBD). MERS-CoV is an enveloped positive-stranded RNA virus, a member of the Betacoronavirus genus, and the causative agent of MERS, an acute respiratory disease that often leads to pneumonia and renal failure. The MERS-CoV spike glycoprotein mediates viral attachment to host cells and virus-cell-mediated membrane fusion during infection. It is composed of an S1 subunit, which contains the RBD that binds to host dipeptidyl peptidase-4 (DPP-4), and an S2 subunit containing heptad repeat regions 1 and 2, which are responsible for membrane fusion, as well as a transmembrane domain and a cytoplasmic tail. The RBD of the MERS-CoV spike glycoprotein is one of the targets for neutralizing antibodies. Cayman's MERS-CoV Spike Glycoprotein RBD (Strain EMC/2012) (recombinant) protein consists of 251 amino acids and has a calculated molecular weight of 27.7 kDa.Synonyms: MERS-CoV Spike Glycoprotein Receptor-Binding Domain, Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein RBD, Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein Receptor-Binding Domain. Purity: >90% as estimated by SDS-PAGE. Endotoxin Testing: <1.0 EU/µg determined by the LAL endotoxin assay. Source: Recombinant MERS-CoV C-terminal His-tagged spike glycoprotein RBD expressed in insect cells. Amino Acids: 367-606. MW: 27.7 kDa. Formulation: (Request formulation change), Lyophilized from sterile 20 mM Tris, 500 mM sodium chloride, 10% glycerol, pH 8.0. UniProt Accession #: K0BRG7.